Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia Inc.
The global CRISPR technology market is expected to grow from $0.8 billion in 2020 to $0.95 billion in 2021 at a compound annual growth rate (CAGR) of 18.8%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.22 billion in 2025 at a CAGR of 24%.
The CRISPR technology market consists of sales of CRISPR technology products and services which is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function.The revenue generated by the market includes the sales of products such as design tools, plasmid & vector, Cas9 & gRNA, libraries & delivery system products and services that include design & vector construction, screening and cell line engineering.
These products and services are used in genome editing/genetic engineering, genetically modifying organisms, agricultural biotechnology and others which include gRNA database/gene library, CRISPR plasmid, human stem cell & cell line engineering by end-users. The end-users include pharmaceutical & biopharmaceutical companies, biotechnology companies, academic & research institutes and contract research organizations.
The CRISPR technology market covered in this report is segmented by product type into design tools, plasmid and vector, CAS9 and G-RNA, delivery system products. It is also segmented by application into genome editing/ genetic engineering, genetically modified organisms, agricultural biotechnology, others and by end-user into industrial biotech, biological research, agricultural research, therapeutics and drug discovery.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period.There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing.
The Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation.In April 2019, the Australian government stated that the Office of the Gene Technology Regulator (OGTR) will regulate only the gene-editing technologies that use a template, or that insert other genetic material into the cell.
According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the market.
In 2019, Cardea Bio Inc., a US-based biotechnology infrastructure company that manufactures biology-gated transistors (Cardean transistors) that utilizes biocompatible graphene instead of silicon and replaces optical signal observations with direct electrical molecular signal analysis, merged with Nanosens Innovations, Inc. The merger is aimed at accelerating the development of the genome sensor that combines Nanosens’ CRISPR-Chip technology with Cardea’s graphene biosensor infrastructure and is the first DNA search engine globally that runs on CRISPR-Chip technology. Nanosens will be operating as a subsidiary of Cardea Bio. Nanosens Innovations, Inc. is a US-based biotechnology company that develops CRISPR-Chip and FEB technology.
The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period.The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19.
In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc’s Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test.This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens.
This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.
Several advancements in CRISPR technology are trending in the market during the period.Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more.
In 2019, a study published in Springer Nature stated the development of an advanced super-precise new CRISPR tool that allows researchers more control over DNA changes.This tool seems to have the capability of providing a wider variety of gene edits which might potentially open up conditions that have challenged gene-editors.
Also, in 2020, another study in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR–Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Our reports have been used by over 10K customers, including:
The global cell counting market grew at a CAGR of around 6% during 2015-2020. Looking forward, the analyst expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
Global Hospital Care Partnering 2014 to 2021 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital...
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
The global flow cytometry market exhibited moderate growth during 2015-2020. Flow cytometry refers to a biophysical and laser-based analytical technology that is used in the analysis of the cells or micelles that are usually suspended in a fluid using a laser beam. This technique aids in subclassifying cell types and...
The global flow cytometry market size is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, growing at a CAGR of 8.1% from 2020 to 2026. The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing...
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest joint...
The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report. This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology, device and diagnostic sectors. Fully revised and updated, the report...
The cleanroom technology market is expected to reach US$ 8,356.97 million by 2028 from US$ 5,233.63 million in 2021; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028. A few factors such as increasing adoption in the biopharmaceuticals industry and technological advancements in cleanrooms are driving the growth of the market. However,...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.